Article

Carl Zeiss Meditec eyes surgical sister company

Jena, Germany—Carl Zeiss Meditec AG said a plan to acquire Carl Zeiss Surgical will expand its role in ophthalmic and neuro/ ENT surgery.

Jena, Germany-Carl Zeiss Meditec AG said a plan to acquire Carl Zeiss Surgical will expand its role in ophthalmic and neuro/ ENT surgery.

In a Jan. 9 news release, the device manufacturer said the acquisition-pending approval at the annual general meeting of Carl Zeiss Meditec AG this month-would make Carl Zeiss Meditec a leading medical technology provider in those specialty areas. Sales would be about Euro 500 million, the company said.

Carl Zeiss Surgical, a manufacturer of surgical microscopes and visualization solutions, is based in Oberkochen, Germany, and serves the U.S. market from an office in Thornwood, NY. It is wholly owned by Carl Zeiss AG, which also owns 65% of Carl Zeiss Meditec. Carl Zeiss Meditec is based in Jena, Germany, with key subsidiaries in the United States and Japan.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
© 2025 MJH Life Sciences

All rights reserved.